Evidence map›Paper›PMID 41174676›Full record

ArticlePilot and feasibility studies2025

Multimethod feasibility evaluation of smoking cessation intervention for patients receiving opioid agonist therapy.

Karl Trygve Druckrey-Fiskaaen, Tesfaye Madebo, Siv-Elin Leirvåg Carlsen, Einar Furulund, Jørn Henrik Vold, Jan Tore Daltveit, Torgeir Gilje Lid, Lars T Fadnes, ATLAS4LAR Study Group

Abstract read
In one paragraph

Article in Pilot and feasibility studies, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Karl Trygve Druckrey-FiskaaenDepartment of Addiction Medicine, Bergen Addiction Research, Haukeland University Hospital, Bergen, Norway. karl.trygve.druckrey-fiskaaen@helse-bergen.no.ORCID http://orcid.org/0000-0002-2905-0613
Tesfaye MadeboDepartment of Addiction Medicine, Bergen Addiction Research, Haukeland University Hospital, Bergen, Norway.
Siv-Elin Leirvåg CarlsenDepartment of Addiction Medicine, Bergen Addiction Research, Haukeland University Hospital, Bergen, Norway.
Einar FurulundDepartment of Addiction Medicine, Bergen Addiction Research, Haukeland University Hospital, Bergen, Norway.
Jørn Henrik VoldDepartment of Addiction Medicine, Bergen Addiction Research, Haukeland University Hospital, Bergen, Norway.
Jan Tore DaltveitDepartment of Addiction Medicine, Bergen Addiction Research, Haukeland University Hospital, Bergen, Norway.
Torgeir Gilje LidCentre for Alcohol and Drug Research, Stavanger University Hospital, Stavanger, Norway.
Lars T FadnesDepartment of Addiction Medicine, Bergen Addiction Research, Haukeland University Hospital, Bergen, Norway.
ATLAS4LAR Study Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAmong patients receiving opioid agonist therapy, 85% are active tobacco smokers. Despite the significant impact of smoking-related pulmonary diseases on disability and mortality in this population, less than 10% successfully quit smoking with current interventions. The study aimed to evaluate the feasibility of integrating a smoking cessation intervention at outpatient clinics for persons receiving opioid agonist treatment. The specific outcomes were the feasibility of integration, intervention acceptability, participant retention, and the trial's impact on smoking behaviour.

methodsWe conducted a 12-week feasibility study among patients receiving OAT (n = 25) in 2021 in Bergen, Norway. The feasibility outcomes were evaluated using qualitative semi-structured interviews and quantitative data collected at study visits during the pilot intervention period.

resultsParticipants reported that intervention was acceptable as it was easily accessible and provided for free at their local OAT clinic. Participants attended a median of 9 out of 12 weekly study visits and 40% of the participants completed all 12 weeks. The median number of cigarettes was reduced from 70 (range 31-175) to 26 (range 6-50) during the intervention period for those who attended all 12 study visits. One participant reported quitting smoking. The participants stressed that the possibility to individually choose smoking medication and tapering regimen was important for the acceptability of the intervention.

conclusionsParticipant retention and qualitative results support the feasibility of the tested intervention, indicating that implementing integrated smoking cessation treatments in opioid agonist therapy clinics was feasible and acceptable to patients. The low number of participants quitting indicated low feasibility for smoking cessation. Simultaneously, the more than halving of the number of cigarettes smoked suggests that the progression of the intervention should have a reduction in the number of cigarettes smoked as the primary aim. However, the impact of this intervention requires thorough evaluation through a sufficiently powered randomised controlled trial.

Indexed as

Feasibility trialMultimethodOpioid agonist treatmentOpioid use disorderSmoking cessationTobacco

Identifiers

PMID41174676
PMCPMC12577004

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.